In a column I wrote a couple years ago, I noted that, despite my fascination with the subject of psychology, I have only an amateur understanding of it. We can add artificial intelligence (AI) to the long list of things I’m not an expert on.…
The two main mouse models used to study myelin damage in multiple sclerosis (MS) each replicate important but distinct biological features of the disease — but both fall short of capturing its full biological complexity, a new study shows. The findings suggest that each of…
Enrollment is half complete in an ongoing clinical study at Massachusetts General Hospital (MGH) testing whether a PET imaging tracer can reliably measure myelin damage in people with multiple sclerosis (MS). The Phase 1 study (NCT04699747) is recruiting about 60 people — healthy adults and MS…
Tweet Many years ago the new target for MS was reported and it was called RASGRP2. People then wanted to inhibit responses to this protein to treat MS…I thought the idea was a crock and I said this to one of the leading authors of…
Dear family and friends, Over the years, I have wondered how my diagnosis of relapsing-remitting multiple sclerosis has impacted your worlds, as well. Just as I am unable to convey the impact of its collision with the life as I once knew, I imagine those…
By Samuel Fitch When people hear the phrase “mental health,” they often think of major life changes, complicated routines, or dramatic breakthroughs. My experience has been much simpler. For me, strong mental health is often built through small habits repeated consistently; … Continue reading → Source:…
Leaders in multiple sclerosis (MS) research and care are preparing to gather in Charlotte, North Carolina, for the Consortium of MS Centers (CMSC) annual meeting, with this year marking the organization’s 40th anniversary. Multiple Sclerosis News Today sat down with the consortium’s CEO, Kathleen Costello,…
Tiziana Life Sciences‘ experimental nasal spray foralumab continues to show signs that it may help slow disability progression and ease fatigue in people with nonactive secondary progressive multiple sclerosis (SPMS), according to new data from an expanded access program (EAP). Fourteen people with nonactive SPMS…
Tweet Evidence-based Medicine is at the cornerstone of the approach to treatment and at the centre of this evidence is clinical trials. To do this properly costs millions of what pounds/Dollars/Euros. In contrast complementary medicines lack this rigour of assessment and it is perhaps not…
The presence of multiple asymptomatic spinal cord lesions — areas of damage, as captured by imaging scans — is associated with about a twofold higher risk of developing multiple sclerosis (MS) for people with a first episode of myelitis, or inflammation of the spinal cord,…